Another AZ exec jumps ship for CEO job at smaller drugmaker

AstraZeneca ($AZN) has lost its second top executive in less than two weeks, as VP James Ward-Lilley bids goodbye to Big Pharma to run the respiratory specialist Vectura--which happens to have partnerships with AZ lung-drug rivals GlaxoSmithKline ($GSK) and Novartis ($NVS). Currently head of AZ's portfolio strategy in respiratory, inflammation and autoimmunity, Ward-Lilley will join Vectura Oct. 1. Story | Release

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.